Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.
Chavez-MacGregor M, Miao J, Pusztai L, Goetz MP, Rastogi P, Ganz PA, Mamounas EP, Paik S, Bandos H, Razaq W, O'Dea A, Kaklamani V, Silber ALM, Flaum LE, Andreopoulou E, Wendt AG, Carney JF, Sharma P, Gralow JR, Lew DL, Barlow WE, Hortobagyi GN.
Chavez-MacGregor M, et al. Among authors: sharma p.
J Clin Oncol. 2024 Jun 4:JCO2302344. doi: 10.1200/JCO.23.02344. Online ahead of print.
J Clin Oncol. 2024.
PMID: 38833643